Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Neutral rating on Apellis Pharmaceuticals (APLS) and lowers the price target from $60 to $52.
April 29, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mizuho has maintained a Neutral rating on Apellis Pharmaceuticals and reduced the price target from $60 to $52.
The reduction in price target by a significant margin suggests a tempered outlook on the company's near-term performance, potentially leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100